Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy

Purpose: We investigated time to pregnancy, efficacy and safety of fertility preservation, and assisted reproductive technologies (ARTs) in women with early hormone receptor-positive breast cancer (BC) desiring future pregnancy.

Patients And Methods: POSITIVE is an international, single-arm, prospective trial, in which 518 women temporarily interrupted adjuvant endocrine therapy to attempt pregnancy. We evaluated menstruation recovery and factors associated with time to pregnancy and investigated if ART use was associated with achieving pregnancy. The cumulative incidence of BC-free interval (BCFI) events was estimated according to the use of ovarian stimulation at diagnosis. The median follow-up was 41 months.

Results: Two hundred seventy-three patients (53%) reported amenorrhea at enrollment, of whom 94% resumed menses within 12 months. Among 497 patients evaluable for pregnancy, 368 (74%) reported at least one pregnancy. Young age was the main factor associated with shorter time to pregnancy with cumulative incidences of pregnancy by 1 year of 63.5%, 54.3%, and 37.7% for patients age <35, 35-39, and 40-42 years, respectively. One hundred and seventy-nine patients (36%) had embryo/oocyte cryopreservation at diagnosis, of whom 68 reported embryo transfer after enrollment. Cryopreserved embryo transfer was the only ART associated with higher chance of pregnancy (odds ratio, 2.41 [95% CI, 1.75 to 4.95]). The cumulative incidence of BCFI events at 3 years was similar for women who underwent ovarian stimulation for cryopreservation at diagnosis, 9.7% (95% CI, 6.0 to 15.4), compared with those who did not, 8.7% (95% CI, 6.0 to 12.5).

Conclusion: In POSITIVE, fertility preservation using ovarian stimulation was not associated with short-term detrimental impact on cancer prognosis. Pregnancy rates were highest among those who underwent embryo/oocyte cryopreservation followed by embryo transfer.

Citing Articles

Cell Populations in Human Breast Cancers are Molecularly and Biologically Distinct with Age.

Parsons A, Colon E, Spasic M, Kurt B, Swarbrick A, Freedman R Res Sq. 2024; .

PMID: 39483921 PMC: 11527348. DOI: 10.21203/rs.3.rs-5167339/v1.

References

Moore H, Unger J, Phillips K, Boyle F, Hitre E, Porter D . Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015; 372(10):923-32. PMC: 4405231. DOI: 10.1056/NEJMoa1413204. View

Garcia D, Brazal S, Rodriguez A, Prat A, Vassena R . Knowledge of age-related fertility decline in women: A systematic review. Eur J Obstet Gynecol Reprod Biol. 2018; 230:109-118. DOI: 10.1016/j.ejogrb.2018.09.030. View

Anderson R, Lambertini M, Hall P, Wallace W, Morrison D, Kelsey T . Survival after breast cancer in women with a subsequent live birth: Influence of age at diagnosis and interval to subsequent pregnancy. Eur J Cancer. 2022; 173:113-122. DOI: 10.1016/j.ejca.2022.06.048. View

Paluch-Shimon S, Cardoso F, Partridge A, Abulkhair O, Azim H, Bianchi-Micheli G . ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5). Ann Oncol. 2022; 33(11):1097-1118. DOI: 10.1016/j.annonc.2022.07.007. View

Lambertini M, Blondeaux E, Agostinetto E, Hamy A, Kim H, Di Meglio A . Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study. JAMA. 2023; 331(1):49-59. PMC: 10704340. DOI: 10.1001/jama.2023.25463. View

Oktay K, Harvey B, Partridge A, Quinn G, Reinecke J, Taylor H . Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018; 36(19):1994-2001. DOI: 10.1200/JCO.2018.78.1914. View

Arecco L, Blondeaux E, Bruzzone M, Ceppi M, Latocca M, Marrocco C . Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. Hum Reprod. 2022; 37(5):954-968. PMC: 9071231. DOI: 10.1093/humrep/deac035. View

Lambertini M, Moore H, Leonard R, Loibl S, Munster P, Bruzzone M . Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. J Clin Oncol. 2018; 36(19):1981-1990. PMC: 6804855. DOI: 10.1200/JCO.2018.78.0858. View

Goldrat O, Kroman N, Peccatori F, Cordoba O, Pistilli B, Lidegaard O . Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome. Eur J Cancer. 2015; 51(12):1490-6. DOI: 10.1016/j.ejca.2015.05.007. View

10.

Condorelli M, De Vos M, Lie Fong S, Autin C, Delvigne A, Vanden Meerschaut F . Impact of ARTs on oncological outcomes in young breast cancer survivors. Hum Reprod. 2020; 36(2):381-389. DOI: 10.1093/humrep/deaa319. View

11.

Anderson R, Amant F, Braat D, DAngelo A, Chuva de Sousa Lopes S, Demeestere I . ESHRE guideline: female fertility preservation. Hum Reprod Open. 2020; 2020(4):hoaa052. PMC: 7666361. DOI: 10.1093/hropen/hoaa052. View

12.

Azim Jr H, Davidson N, Ruddy K . Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer. Am Soc Clin Oncol Educ Book. 2016; 35:23-32. DOI: 10.1200/EDBK_159069. View

13.

Lambertini M, Blondeaux E, Bruzzone M, Perachino M, Anderson R, de Azambuja E . Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. J Clin Oncol. 2021; 39(29):3293-3305. DOI: 10.1200/JCO.21.00535. View

14.

Partridge A, Niman S, Ruggeri M, Peccatori F, Azim Jr H, Colleoni M . Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. Breast. 2021; 59:327-338. PMC: 8365381. DOI: 10.1016/j.breast.2021.07.021. View

15.

Azim Jr H, Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameye L . Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol. 2012; 31(1):73-9. PMC: 3530692. DOI: 10.1200/JCO.2012.44.2285. View

16.

Ruddy K, Gelber S, Tamimi R, Ginsburg E, Schapira L, Come S . Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol. 2014; 32(11):1151-6. PMC: 4164759. DOI: 10.1200/JCO.2013.52.8877. View

17.

Kim J, Turan V, Oktay K . Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer. J Clin Endocrinol Metab. 2016; 101(4):1364-71. PMC: 4880171. DOI: 10.1210/jc.2015-3878. View

18.

Lambertini M, Peccatori F, Demeestere I, Amant F, Wyns C, Stukenborg J . Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2020; 31(12):1664-1678. DOI: 10.1016/j.annonc.2020.09.006. View

19.

Oktay K, Marin L, Titus S . Impact of chemotherapy on the ovarian reserve: Are all primordial follicles created equal?. Fertil Steril. 2022; 117(2):396-398. DOI: 10.1016/j.fertnstert.2021.12.007. View

20.

Azim A, Costantini-Ferrando M, Oktay K . Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008; 26(16):2630-5. DOI: 10.1200/JCO.2007.14.8700. View